West Pharmaceutical Services Business Combination, Contingent Consideration, Liability increased by 36.4% to $3.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 25.0%, from $2.40M to $3.00M. Over 5 years (FY 2020 to FY 2025), Business Combination, Contingent Consideration, Liability shows a downward trend with a -9.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase suggests the acquired business is meeting or exceeding performance targets, which will require higher future cash payouts.
This represents the fair value of a liability recognized when the company is obligated to pay additional consideration t...
This is a standard liability for companies pursuing aggressive M&A strategies with performance-based earn-out structures.
other_business_combination_contingent_consideration_liability| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.60M | $3.50M | $3.70M | $4.00M | $4.00M | $4.90M | $4.70M | $4.50M | $4.30M | $4.00M | $3.60M | $3.70M | $3.80M | $3.70M | $3.00M | $2.40M | $2.30M | $2.80M | $2.20M | $3.00M |
| QoQ Change | — | -2.8% | +5.7% | +8.1% | +0.0% | +22.5% | -4.1% | -4.3% | -4.4% | -7.0% | -10.0% | +2.8% | +2.7% | -2.6% | -18.9% | -20.0% | -4.2% | +21.7% | -21.4% | +36.4% |
| YoY Change | — | — | — | — | +11.1% | +40.0% | +27.0% | +12.5% | +7.5% | -18.4% | -23.4% | -17.8% | -11.6% | -7.5% | -16.7% | -35.1% | -39.5% | -24.3% | -26.7% | +25.0% |